Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Antiretroviral therapy (ART) initiation is associated with a significant loss of bone mineral
density (BMD), characterised by increases in bone turnover, which is largely limited to the
first 48 weeks of therapy. Bisphosphonates, such as alendronate, decrease bone turnover and
can limit loss of bone mineral density.
This study aims to determine if a short course of treatment with the oral bisphosphonate
alendronate can limit loss of bone mineral density associated with initiation of ART in HIV-1
infected, antiretroviral naive, adult subjects.
Phase:
Phase 4
Details
Lead Sponsor:
University College Dublin
Collaborators:
Beaumont Hospital Health Research Board, Ireland Mater Misericordiae University Hospital Royal College of Surgeons, Ireland Rush University Medical Center
Treatments:
Alendronate Calcium Calcium Carbonate Calcium, Dietary Cholecalciferol Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Ergocalciferols Tenofovir Vitamin D Vitamins